The Clinical Studies Core is an integral component the Translational Center as it is designed to 1) Assist investigators in accessing, selecting, and recruiting cystic fibrosis and control patients for clinical trials and to husband the patient resources of the Center. 2) Assist investigators in the planning and execution of clinical trials, 3) Provide oversight and/or performance of tests and procedures, including quality control. 4) Provide oversight of collection and processing of biologic specimens, including SAL fluid and cell samples, nasal lavage fluid/cells and nasal epithelial cells from scrapping, sputum (induced and expectorated), exhaled breath condensate, blood, urine, and stool, 5) Maintain a specimen and tissue bank of samples collected from current arid former patients 6) Maintain the database for all patients ever seen at the Cleveland CF Center since its inception (1619 total patients;348 active patients) for purposes of patient selection for clinical trials and studies, retrospective clinical studies and cooperation with various national databases. 7) Facilitate the translation of discoveries made by basic science investigators into clinical investigation where applicable, including the development of outcome measures appropriate for specific studies;and to engage basic scientists to investigate questions identified in clinical practice or clinical studies. This Core makes available our well-characterized patient population for clinical studies and facilitates the bench to bedside translation of ideas from our basic science labs. The Core-supported clinical projects also generate hypotheses that are in turn returned to basic science labs for more detailed investigation.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-7 (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Dasenbrook, Elliott C; Konstan, Michael W; VanDevanter, Donald R (2015) Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J Cyst Fibros 14:370-5
Than, B L N; Goos, J A C M; Sarver, A L et al. (2014) The role of KCNQ1 in mouse and human gastrointestinal cancers. Oncogene 33:3861-8
Xu, Weiling; Janocha, Allison J; Leahy, Rachel A et al. (2014) A novel method for pulmonary research: assessment of bioenergetic function at the air-liquid interface. Redox Biol 2:513-9
Boyle, Michael P; Bell, Scott C; Konstan, Michael W et al. (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2:527-38
Doring, Gerd; Bragonzi, Alessandra; Paroni, Moira et al. (2014) BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J Cyst Fibros 13:156-63
Spilker, Theodore; Leber, Amy L; Marcon, Mario J et al. (2014) A simplified sequence-based identification scheme for Bordetella reveals several putative novel species. J Clin Microbiol 52:674-7
Zaman, Khalequz; Bennett, Deric; Fraser-Butler, Maya et al. (2014) S-Nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface. Biochem Biophys Res Commun 443:1257-62
VanDevanter, Donald R; Pasta, David J; Konstan, Michael W (2014) Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012. J Pediatr 165:1091-1097.e2
Caretti, Anna; Bragonzi, Alessandra; Facchini, Marcella et al. (2014) Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis. Biochim Biophys Acta 1840:586-94
Kerem, Eitan; Konstan, Michael W; De Boeck, Kris et al. (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2:539-47

Showing the most recent 10 out of 274 publications